A Study in Healthy Subjects to Investigate Whether Administration of Lucerastat Can Affect Normal Heart Function

Inclusion Criteria: Part A only: \- Healthy male subjects aged between 18 and 55 years. Part B only: * Healthy male and female subjects aged between 18 and 55 years. * Women of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day 1 pre-dose of the first period. They must consistently and correctly use a highly effective method of contraception, or be sexually inactive, or have a vasectomized partner. * Women of nonchildbearing potential (i.e., postmenopausal, XY genotype, Turner syndrome, uterine agenesis). Part A and B: * Signed informed consent prior to any study-mandated procedure. * Body mass index of 18.0 to 30.0 kg/m2 (inclusive) at Screening. Body weight at least 50.0 kg at Screening and prior to first study treatment administration. * Healthy on the basis of medical history, physical examination, cardiovascular assessments and clinical laboratory tests. Exclusion Criteria: Part B only: * Known hypersensitivity to moxifloxacin or any of its excipients. * Pregnant or lactating women. * Women planning to become pregnant. Part A and B: * Previous exposure to lucerastat. * Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol. * History or presence of rhythm disorders.